These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21282424)

  • 1. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1571-9. PubMed ID: 21282424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
    Nielsen EI; Viberg A; Löwdin E; Cars O; Karlsson MO; Sandström M
    Antimicrob Agents Chemother; 2007 Jan; 51(1):128-36. PubMed ID: 17060524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
    Harper T; Miller D; Flynn HW
    Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2522-6. PubMed ID: 9371360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
    Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
    MacGowan AP; Bowker KE; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J; Vidaillac C; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4329-34. PubMed ID: 20696880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F; Pavan F; Lugatti E; Dolcet F; Talmassons G; Screm MC; Furlanut M
    Clin Pharmacokinet; 2006; 45(3):287-95. PubMed ID: 16509760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
    Grossi O; Caillon J; Arvieux C; Jacqueline C; Bugnon D; Potel G; Hamel A
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3401-3. PubMed ID: 17576849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
    MacGowan AP; Reynolds R; Noel AR; Bowker KE
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5181-4. PubMed ID: 19805569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model.
    Odenholt I; Löwdin E; Gustafsson I; Cars O
    Antimicrob Agents Chemother; 2002 Jun; 46(6):2046-8. PubMed ID: 12019138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.